Overcoming Resistance in Prostate Cancer Therapy Using a DZ-Simvastatin Conjugate-Reference-Cited by-同舟云学术

Overcoming Resistance in Prostate Cancer Therapy Using a DZ-Simvastatin Conjugate

Published:2024-01-17 Issue:2 Volume:21 Page:873-882
ISSN:1543-8384
Container-title:Molecular Pharmaceutics
language:en
Short-container-title:Mol. Pharmaceutics

Author:

Ou Yan¹,Chu Gina Chia-Yi¹,Lyu Ji¹,Yin Liyuan¹,Lim Adrian¹,Zhai Ning¹,Cui Xiaojiang²³,Lewis Michael S.⁴⁵,Edderkaoui Mouad¹³,Pandol Stephen J.¹³,Wang Ruoxiang¹³,Zhang Yi⁶^ORCID

Affiliation:

1. Department of Medicine, Cedars-Sinai Medical Center, 8700 Beverly Boulevard, Los Angeles, California 90048, United States

2. Department of Surgery, Cedars-Sinai Medical Center, 8700 Beverly Blvd, Los Angeles, California 90048, United States

3. Samuel Oschin Comprehensive Cancer Center, Cedars-Sinai Medical Center, 8700 Beverly Boulevard, Los Angeles, California 90048, United States

4. Department of Pathology, Cedars-Sinai Medical Center, 8700 Beverly Boulevard, Los Angeles, California 90048, United States

5. VA Greater Los Angeles Healthcare System, 11301 Wilshire Boulevard, Los Angeles, California 90073, United States

6. Department of Biomedical Sciences, Cedars-Sinai Medical Center, 8700 Beverly Boulevard, Los Angeles, California 90048, United States

Funder

National Cancer Institute

Clinical and Translational Science Institute, University of California, Los Angeles

DOD Peer Reviewed Cancer Research Program

Cedars-Sinai Cancer Developmental Funds

Publisher

American Chemical Society (ACS)

Link

https://pubs.acs.org/doi/pdf/10.1021/acs.molpharmaceut.3c00993

Reference44 articles.

1. Advanced Androgen Blockage in Nonmetastatic Castration-resistant Prostate Cancer: An Indirect Comparison of Apalutamide and Enzalutamide

2. Comparison of effectiveness and safety outcomes of abiraterone versus enzalutamide in patients with metastatic castration-resistant prostate cancer: a systematic review and meta-analysis

3. Analysis of Side Effect Profile of Alopecia, Nail Changes, Peripheral Neuropathy, and Dysgeusia in Prostate Cancer Patients Treated With Docetaxel and Cabazitaxel

4. Inhibitory effect of roburic acid in combination with docetaxel on human prostate cancer cells

5. Therapy resistance: opportunities created by adaptive responses to targeted therapies in cancer